Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLX-112 for Levodopa-induced Dyskinesia in Parkinson's Disease
NCT05148884Phase 2Completed
- Sponsor
- Neurolixis
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing NLX-112 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events at 10 weeks, Number of Participants With Any Clinically Significant Changes From Baseline in Electrocardiogram at Day 70 and 4 more. Started Nov 2021; status: completed.
02
Drugs
NLX-112
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT05148884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148884.